

Improving Clinical Outcomes and Patient Satisfaction in Ulcerative Colitis

Tweetorial #2 References

Tweet 2:

Armuzzi A, Tarallo M, Lucas J, et al. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. *BMC Gastroenterol*. 2020;20(1). doi:10.1186/s12876-020-1164-0

Danese S, Allez M, van Bodegraven A, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. *Dig Dis*. 2019;37(4):266-283. doi:10.1159/000496739

Tweet 5:

Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. *Gastroenterol Clin North Am*. 2014;43(3):603-617. doi:10.1016/j.gtc.2014.05.011

Tweet 6:

Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2017;376(18):1723-1736. doi:10.1056/nejmoa1606910

Tweet 7:

Sands BE, Armuzzi A, Marshall JK, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. *Aliment Pharmacol Ther*. 2020;51(2):271-280. doi:10.1111/apt.15555

Tweet 8:

Gilead Sciences, Inc. Gilead And Galapagos announce positive topline results of Phase 2b/3 trial of filgotinib in moderately to severely active ulcerative colitis. May 20, 2020. Accessed October 28, 2020. <https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gilead-and-galapagos-announce-positive-topline-results-of-phase-2b3-trial-of-filgotinib-in-moderately-to-severely-active-ulcerative-colitis>

Tweet 9:

Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. *Gastroenterology*. 2020;158(8):2139-2149.e14. doi:10.1053/j.gastro.2020.02.030

Tweet 11:

Argollo M, Furfaro F, Gilardi D, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. *Expert Opin Biol Ther*. 2020;20(4):413-420. doi:10.1080/14712598.2020.1732919

Tweet 12:

Bristol Myers Squibb. Bristol Myers Squibb announces positive topline results from pivotal Phase 3 True North Trial evaluating Zeposia (ozanimod) in patients with moderate to severe ulcerative colitis. June 02, 2020. Accessed October 28, 2020. <https://news.bms.com/news/corporate-financial/2020/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-True-North-Trial-Evaluating-Zeposia-ozanimod-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspx>

Tweet 13:

Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. *Gastroenterology*. 2020;158(3):550-561. doi:10.1053/j.gastro.2019.10.035